Carbocalcitonin treatment in Sudeck's atrophy.
The efficacy of new calcitonin, the amino analog of eel calcitonin (carboCT) on Sudeck's atrophy of the foot was investigated in 14 patients. CarboCT was administered at the dose of 40 Medical Research Council (MRC) units per day, and the duration of treatment was two to ten months. No adverse effects were noted. Bone pain and local edema decreased associated with improvement of motility. CarboCT induced a slight decrease in plasma calcium, plasma phosphate, and 24-hour urinary calcium excretion. An increase in cAMP/Cr ratio, an index of parathyroid function, was also observed (probably a manifestation of the hypocalcemic effect of calcitonin and secondary parathyroid stimulation). The whole body retention of 99mTc-MDP represents a valuable index of bone turnover, it decreased progressively and significantly on treatment. A dynamic study of local bone uptake of 99mTC-MDP was performed in eight patients. After carboCT therapy, statistically significant decreases in local blood flow, early uptake, and delayed uptake were appreciated in the involved foot. These findings lead to the conclusion that carboCT is effective in the treatment of Sudeck's atrophy.
D000328:Adult; D000368:Aged; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000378:metabolism; D002116:Calcitonin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D012019:Reflex Sympathetic Dystrophy / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D013669:Technetium Tc 99m Medronate; D013997:Time Factors; D014915:Whole-Body Counting
D002116:Calcitonin; C012755:elcatonin; D013669:Technetium Tc 99m Medronate